New insights into Brilinta

Published: 2012-08-06 06:58:00

Updated: 2012-08-06 06:58:00

The efficacy of AstraZeneca’s Brilinta (ticagrelor), a platelet aggregation inhibitor, has been re-evaluated in advanced countries including the United States, United Kingdom and Germany.

In a study of 44 American patients with acute coronary syndromes (ACS) who did not respond to clopidogrel,...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK